Emergent BioSolutions Awarded $29M 5-Year Contract To Develop A Dry Formulation Of NuThrax, A Next Generation Anthrax Vaccine

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a contract with the National Institute of Allergy and ...